Month: February 2024

EEZY PLC — FINANCIAL STATEMENTS BULLETIN   — 15 FEBRUARY 2024 AT 8:00 Eezy Plc’s Financial Statements Bulletin 1-12/2023: Profitability improvement program implemented – renewed strategy sets a clear direction October–December 2023Revenue was EUR 52.1 million (EUR 62.2 million in October–December 2022). Revenue decreased by 16%. EBITDA was EUR 3.6 million (4.6). EBIT was EUR -0.7 million (2.7) and was -1.3% of revenue (4.3%). EBIT includes an impairment of EUR 2.3 million on trademarks and customer relationships related to acquisitions. Earnings per share was EUR -0.06 (0.08). A profitability improvement program was implemented, and the strategy renewal project was started. EUR 0.8 million in personnel expenses related to severance payments were recorded in the result.January–December 2023Revenue was EUR 219.0 million...

Marimekko Corporation, Stock Exchange Release, 15 February 2024 at 7.55 a.m. Change in Marimekko’s financial reporting dates in 2024 Marimekko Corporation changes the publication date of its Interim Report for January–September 2024. The new publishing date is Wednesday 6 November 2024. In 2024, Marimekko Corporation will publish financial information as follows:Financial Statement Bulletin 2023 on Thursday 15 February 2024 at 8.00 a.m. Interim Report 1 January–31 March 2024 on Wednesday 15 May 2024 at 8.00 a.m. Half-year Financial Report 1 January–30 June 2024 on Thursday 15 August 2024 at 8.00 a.m. Interim Report 1 January–30 September 2024 on Wednesday 6 November 2024 at 8.00 a.m.Marimekko observes a silent period of 30 days prior to publishing of financial information. The company’s Financial Statements and the Report of the Board...

CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant Clermont-Ferrand, France, 15 February 2024 (06.45am CET) CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, and De Smet Engineers & Contractors (DSEC), a world-class provider of Engineering, Procurement and Construction services in the biotech’s and agro-processing industries, jointly announce their collaboration to spearhead the construction of the world’s first PET biorecycling plant. Under the agreement, De Smet has been entrusted with the project management and detailed engineering, including procurement assistance and CARBIOS partners’ management, to ensure the execution...

Perth, Feb. 15, 2024 (GLOBE NEWSWIRE) — HALF YEAR RESULTS INVESTOR WEBINAR / CALL Perth, Western Australia/February 15, 2024/Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its December 2023 Half Year Results, which are anticipated for release around 8:30am AEDT on Friday February 23, 2024. CALL DETAILSAustralia: Friday February 23, 2024 Perth – 6:00am Sydney/Melbourne – 9:00am Canada: Thursday February 22, 2024 Vancouver – 2:00pm Toronto – 5:00pm UK: Thursday February 22, 2024 London – 10:00pmRegister for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_TAIUT0pyTSeb3nbeTXF2jg After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock. The gross...

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) an Orphan-Drug Designation (ODD) following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. This follows the Rare Pediatric Disease Designation (RPDD) granted by FDA last month. Mesoblast Chief Executive Silviu Itescu said: “We are very pleased to have now been granted both Orphan-Drug Designation and Rare Pediatric Disease Designation by FDA for REVASCOR in the treatment of children with this often-fatal congenital...